Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: study protocol for a randomized controlled trial
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Maternal obesity is associated with increased risks of adverse pregnancy-related complications and outcomes for both mothers and infants. Overweight and obese women have an increased risk of pregnancy-induced hypertension, preeclampsia and gestational diabetes mellitus (GDM). Infant Body Mass index (BMI) and the risk of obesity in adulthood are related to maternal gestational weight gain (GWG). Preventive lifestyle and dietary interventions are time-consuming and do not always reduce GWG or the risk of maternal pregnancy complications. Recent research has indicated that the gut microbiota may play a significant role in the development of obesity. Some studies have indicated that the daily consumption of probiotics may reduce the risk of preeclampsia, maintain serum insulin levels and reduce the frequency of GDM in pregnant women. The aims of this study are to investigate whether daily probiotic supplements in obese women during pregnancy can limit gestational weight gain, improve glucose homeostasis and thereby improve maternal, fetal and infant health outcomes. METHODS: will be randomized to receive daily probiotics (four capsules of Vivomixx®; total of 450 billion CFU/day, including eight probiotic bacterial strains) or placebo from gestational age 14-20 weeks until delivery. The infants will be followed until 9 months of age. The women will be monitored by weight, blood, fecal, vaginal and urine samples, diet questionnaires and hospital record review. Primary outcomes are: maternal weight gain, glycated hemoglobin (HbA1c) level and changes in glucose concentration measured during an oral glucose tolerance test. Secondary outcomes are: microbiota and inflammatory markers in mother and child, pregnancy complications, pregnancy outcomes, physical activity and the body composition of the neonate. DISCUSSION: We expect to find alterations in the metabolic profiles, microbiota and possibly pregnancy outcomes. From a clinical point of view the effects of Vivomixx® could control weight gain and reduce complications during pregnancy by inducing changes in the gut microbiota. Furthermore, this intervention during pregnancy could influence the infant's microbiota, which could have important implications for infant development and health. TRIAL REGISTRATION: ClincalTrials.gov Identifier: NCT02508844 , registered on 11 May 2015.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Boney, C. M., Verma, A., Tucker, R., & Vohr, B. R. (2005) · Pediatrics · doi:10.1542/peds.2004-1808 · Cited by 2,303
Factors influencing the composition of the intestinal microbiota in early infancy
Penders, J., Thijs, C., Vink, C., Stelma, F. F., Snijders, B., Kummeling, I., van den Brandt, P. A., & Stobberingh, E. E. (2006) · PEDIATRICS · doi:10.1542/peds.2005-2824 · Cited by 2,232
The Hyperglycemia and Adverse Pregnancy Outcome Study
Catalano, P. M., McIntyre, H. D., Cruickshank, J. K., McCance, D. R., Dyer, A. R., Metzger, B. E., Lowe, L. P., Trimble, E. R., Coustan, D. R., Hadden, D. R., et al. (2012) · Diabetes Care · doi:10.2337/dc11-1790 · Cited by 954 · cited 1×
“weight of over 4000 g) and neonatal hypoglycemia [4, 5].”
Beneficial metabolic effects of a probiotic via butyrate-induced GLP-1 hormone secretion
Yadav, H., Lee, J.-H., Lloyd, J., Walter, P., & Rane, S. G. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.452516 · Cited by 709
Sood, A., Midha, V., Makharia, G. K., Ahuja, V., Singal, D., Goswami, P., & Tandon, R. K. (2009) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2009.07.016 · Cited by 513
Tursi, A., Brandimarte, G., Papa, A., Giglio, A., Elisei, W., Giorgetti, G. M., Forti, G., Morini, S., Hassan, C., Pistoia, M. A., et al. (2010) · American Journal of Gastroenterology · doi:10.1038/ajg.2010.218 · Cited by 489
Alisi, A., Bedogni, G., Baviera, G., Giorgio, V., Porro, E., Paris, C., Giammaria, P., Reali, L., Anania, F., & Nobili, V. (2014) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.12758 · Cited by 471
Aagaard, K., Petrosino, J., Keitel, W., Watson, M., Katancik, J., Garcia, N., Patel, S., Cutting, M., Madden, T., Hamilton, H., et al. (2013) · The FASEB Journal · doi:10.1096/fj.12-220806 · Cited by 383 · cited 1×
“found to be suitable in similar clinical studies [31].”
BackgroundDiamant, M., Blaak, E. E., & de Vos, W. M. (2011) · Obesity Reviews · doi:10.1111/j.1467-789x.2010.00797.x · Cited by 308 · cited 1×
“In other animal models, associations have been found between changes in gut flora and obesity, insulin resistance and diabetes [17].”
BackgroundRajkumar, H., Mahmood, N., Kumar, M., Varikuti, S. R., Challa, H. R., & Myakala, S. P. (2014) · Mediators of Inflammation · doi:10.1155/2014/348959 · Cited by 301 · cited 1×
“01), decreased C-reactive protein (CRP), and a favorable effect on the composition of gut microbiota [26].”
Background
Cited by
Treatment strategies against diabetes: Success so far and challenges ahead.
Khursheed, R., Singh, S. K., Wadhwa, S., Kapoor, B., Gulati, M., Kumar, R., Ramanunny, A. K., Awasthi, A., & Dua, K. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172625 · Cited by 239
Gupta, V., Mastromarino, P., & Garg, R. (2024) · Clinical Infectious Diseases · doi:10.1093/cid/ciad766 · Cited by 80
Probiotics for preventing gestational diabetes
Davidson, S. J., Barrett, H. L., Price, S. A., Callaway, L. K., & Dekker Nitert, M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009951.pub3 · Cited by 76
Maternal microbiome in preeclampsia pathophysiology and implications on offspring health
Ishimwe, J. A. (2021) · Physiological Reports · doi:10.14814/phy2.14875 · Cited by 45
“There is mounting evidence supporting the involvement of the microbiome in cardiovascular healthrelated disorders that are also known to be risk factors for | 3 of 19ISHIMWE preeclampsia including obesity and diabetes (Crusell et al., 2018, 2020; Halkjaer et al., 2016; Xue et al., 2014).”
Background
Metadata
- Authors
- Halkjaer, S. I., Nilas, L., Carlsen, E. M., Cortes, D., Halldórsson, T. I., Olsen, S. F., Pedersen, A. E., Krogfelt, K. A., & Petersen, A. M.
- Venue
- Trials
- Published
- 2016-10-11
- Volume
- 17
- Issue
- 1
- Pages
- 491-491
- ISSN
- 1745-6215 (ISSN-L)
- OpenAlex
- W2530129114
- Cited by
- 39
- References
- 14
- FWCI
- 3.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: study protocol for a randomized controlled trial. https://app.cochat.ai/papers/10.1186/s13063-016-1617-5
- The paper
- Halkjaer, S. I., Nilas, L., Carlsen, E. M., Cortes, D., Halldórsson, T. I., Olsen, S. F., Pedersen, A. E., Krogfelt, K. A., & Petersen, A. M. (2016). Effects of probiotics (Vivomixx®) in obese pregnant women and their newborn: study protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/s13063-016-1617-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.